A gene expression signature for insulin resistance
Article
Article Title | A gene expression signature for insulin resistance |
---|---|
ERA Journal ID | 14629 |
Article Category | Article |
Authors | Konstantopoulos, Nicky (Author), Foletta, Victoria C. (Author), Segal, David H. (Author), Shields, Katherine A. (Author), Sanigorski, Andrew (Author), Windmill, Kelly (Author), Swinton, Courtney (Author), Connor, Tim (Author), Wanyonyi, Stephen (Author), Dyer, Thomas D. (Author), Fahey, Richard P. (Author), Watt, Rose A. (Author), Curran, Joanne E. (Author), Molero, Juan C. (Author), Krippner, Guy (Author), Collier, Greg R. (Author), James, David E. (Author), Blangero, John (Author), Jowett, Jeremy B. (Author) and Walder, Ken R. (Author) |
Journal Title | Physiological Genomics |
Journal Citation | 43 (3), pp. 110-120 |
Number of Pages | 11 |
Year | 2011 |
Publisher | American Physiological Society |
Place of Publication | United States |
ISSN | 1094-8341 |
1531-2267 | |
Digital Object Identifier (DOI) | https://doi.org/10.1152/physiolgenomics.00115.2010 |
Web Address (URL) | https://journals.physiology.org/doi/full/10.1152/physiolgenomics.00115.2010 |
Abstract | Insulin resistance is a heterogeneous disorder caused by a range of genetic and environmental factors, and we hypothesize that its etiology varies considerably between individuals. This heterogeneity provides significant challenges to the development of effective therapeutic regimes for long-term management of type 2 diabetes. We describe a novel strategy, using large-scale gene expression profiling, to develop a gene expression signature (GES) that reflects the overall state of insulin resistance in cells and patients. The GES was developed from 3T3-L1 adipocytes that were made “insulin resistant” by treatment with tumor necrosis factor-α (TNF-α) and then reversed with aspirin and troglitazone (“resensitized”). The GES consisted of five genes whose expression levels best discriminated between the insulin-resistant and insulin-resensitized states. We then used this GES to screen a compound library for agents that affected the GES genes in 3T3-L1 adipocytes in a way that most closely resembled the changes seen when insulin resistance was successfully reversed with aspirin and troglitazone. This screen identified both known and new insulin-sensitizing compounds including nonsteroidal anti-inflammatory agents, β-adrenergic antagonists, β-lactams, and sodium channel blockers. We tested the biological relevance of this GES in participants in the San Antonio Family Heart Study (n = 1,240) and showed that patients with the lowest GES scores were more insulin resistant (according to HOMA_IR and fasting plasma insulin levels; P < 0.001). These findings show that GES technology can be used for both the discovery of insulin-sensitizing compounds and the characterization of patients into subtypes of insulin resistance according to GES scores, opening the possibility of developing a personalized medicine approach to type 2 diabetes. |
Keywords | microarray; screening; diabetes;personalized medicine; tumor-necrosis-factor; |
Contains Sensitive Content | Does not contain sensitive content |
ANZSRC Field of Research 2020 | 320208. Endocrinology |
320213. Medical genetics (excl. cancer genetics) | |
Public Notes | Files associated with this item cannot be displayed due to copyright restrictions. |
Institution of Origin | University of Southern Queensland |
Byline Affiliations | Deakin University |
Baker Heart and Diabetes Institute, Australia | |
Texas Biomedical Research Institute, United States | |
Verva Pharmaceuticals, Australia | |
ChemGenex Pharmaceuticals, Australia | |
Garvan Institute of Medical Research, Australia |
https://research.usq.edu.au/item/q3x20/a-gene-expression-signature-for-insulin-resistance
1394
total views10
total downloads1
views this month0
downloads this month